Irene Rossi

Irene Rossi is currently the Head of New Modalities Pharmaceutical Development at Nanopharm Ltd, An Aptar Pharma Company (UK).
She obtained a MSc in Pharmaceutical Chemistry and Technology in 2014 and a PhD in Drugs, Biomolecules and Health Products at the Food and Drug Department, University of Parma (Italy) in 2019.
She joined Nanopharm in 2019 and she currently leads a group focused on the development of new formulation technologies and platforms for OINDP products, working closely with the wider Aptar Pharma team.
Her main research area is the production, optimization and characterization of powders and liquid formulations for nasal and inhalation containing small (i.e. antibiotics and new chemical entities) or large molecules (i.e. protein, antibodies, nucleic acids). She has a strong expertise in spray drying and aerodynamic characterization.
During her PhD, she spent six months at the University of New Mexico, College of Pharmacy (NM, USA), where she acquired competences on cell and bacteria in vitro culture and infection and in vivo animal studies.
She was selected as finalist for The Pat Burnell New Investigator Award in 2017 with a work on pulmonary vaccination against Human Papillomavirus and, again, in 2018 with a work on the development of spray dried polymeric nano-embedded microparticles for tuberculosis and not tuberculous mycobacterial infections.
Up to date, Irene has published 5 original papers, 1 review article, a patent application on the development of a dry powder for pulmonary vaccination and she presented her work at more than 20 international conferences.